Sutro Biopharma , Inc. (NASDAQ:STRO), a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs), has recently undergone a significant transformation in its ...

Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%. The company had revenue of $14.00 million for the quarter, compared to the consensus estimate of $10 ...

NASDAQ:STRO opened at $0.81 on Friday. Sutro Biopharma has a 12 month low of $0.81 and a 12 month high of $6.13. The firm has a market capitalization of $66.80 million, a PE ratio of -0.50 and a ...

On Monday, H.C. Wainwright analysts revised their stance on Sutro Biopharma (NASDAQ: NASDAQ:STRO), downgrading the stock from "Buy" to "Neutral." Alongside this change, they significantly lowered ...

SOUTH SAN FRANCISCO, Calif., March 15, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody ...

H.C. Wainwright downgraded Sutro Biopharma (STRO) to Neutral from Buy with a price target of $2, down from $12, after the company announced a strategic realignment focused on advancing its next ...

Sutro Biopharma (STRO) announced expanded data in a late-breaking oral presentation from the dose-optimization portion of the REFRalphaME-O1 trial with luveltamab tazevibulin in patients with ...

Revenue: US$62.0m (down 60% from FY 2023). Net loss: US$227.5m (loss widened by 113% from FY 2023). US$2.96 loss per share (further deteriorated from US$1.78 loss in FY 2023). Revenue exceeded ...

(RTTNews) - Sutro Biopharma Inc. (STRO) announced expanded data in a late-breaking oral presentation from the dose-optimization portion of the REFRaME-O1 trial with luveltamab tazevibulin (luvelta ...

The search operation to locate seven persons trapped inside the partially collapsed SLBC tunnel here continued at a rapid pace for the 21st day on Friday. Rescue operation underway to locate ...

March 15, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today ...